Kintsugi Voice is an API-first platform, we are developing novel voice biomarker infrastructure to detect signs of clinical depression and anxiety from short clips of free form speech. We help healthcare organizations scale access to mental healthcare with smarter, more accurate triage. Our technology supports multiple use-cases to help more people get the right care at the right time.  We focus on early detection that allows you to lower cost and improve patient outcomes. We have created the first clinical-grade voice biomarker diagnostic (U.S. Patent-Pending and FDA De Novo pending) to measure the severity of depression and anxiety in real-time.

Web-based clinical intelligence platform, primarily utilized in critical care units to guide clinical decisions. The platform has full interoperability with the Electronic Health Record, and combines all relevant data within the complex critical care environment into one visualization to provide a full picture of a patient and their longitudinal trends. FDA-cleared algorithms continually assess the incoming patient information and provide early warning signs of clinical deterioration to aid care teams with determining interventions and treatment. Automated clinical workflows, customized to each individual ICU, provide care efficiency and positively impact clinical outcomes. 

Published clinical outcomes showing:

• Up to 36% reduction in ICU length of stay
• 41% reduction in ICU readmissions
• 22% reduction in time on ventilation
• 18% reduction in time on vasoactive medication

Commercial stage company with market leading AI clinical decision support platform for bedside and remote monitoring of high acuity patients. Published outcomes and strong ROI; utilized in 40+ hospitals & health systems.

1. Kintsugi Voice only needs 20 seconds of free from speech vs. a manual screen that takes roughly 10 minutes.
2. Kintsugi Voice is language agnostic and does not listen to what a patient is saying, but how they are saying it.
3. Kintsugi has the largest annotated patient data model, validated by a psychiatrist team with more than 7 years experience. This allows us to predict depression and anxiety with high specificity and severity, based off of PHQ-9 standards.
4. Kintsugi Voice’s flexible API enables hundreds of workflows from retrospective to live in-call scoring. Typical depression screenings are typically delivered 1 time and not longitudinal. We provide the ability to longitudinally track patients across a period of time.

1. We are not a NLP tool, we do not need any canned speech and or paragraph read to detect depression and or anxiety.
2. We have the largest annotated data model in the world with over 35k patients.
3. We are supporting over 1M at risk lives.
4. 2X accuracy rating compared to the standard of care.

Etiometry provides functionality to seamlessly extend the EHR to be effective for care in high-acuity patient settings (e.g. ICU), including automating clinical workflows, and providing in-depth, longitudinal trends.

Etiometry is the only CDS platform with 4 FDA-cleared risk algorithms and the platform's data collection capabilities have led to a vastly larger number of supporting clinical studies (>150).